ADVL0311 A PHASE I STUDY OF PEMETREXED (LY231514)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是培美曲塞（LY231514, Alimta）治疗复发性实体瘤儿童和青少年的I期研究。培美曲塞是一种抑制多种靶点的新型抗叶酸药。抗代谢物是细胞毒性药物，其结构类似于合成嘧啶、嘌呤和核酸所需的天然分子。培美曲塞通过抑制几种关键的叶酸需要酶，包括胸苷酸合成酶（TS）、二氢叶酸还原酶（DHFR）和甘氨酸酰胺核糖核苷酸甲酰基转移酶（GARFT），具有抗肿瘤活性。研究建议继续累积患者并遵循指定的升级方案。一旦达到了MTD，就应该将该代理移动到第二阶段设置

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase I study of pemetrexed (LY231514, Alimta) in children and adolescents with recurrent solid tumors. Pemetrexed is a novel antifolate that inhibits multiple targets. Antimetabolites are cytotoxic drugs structurally similar to naturally occurring molecules necessary for the synthesis of pyrimidines, purines, and nucleic acids. Pemetrexed has anti-tumor activity through inhibition of several key folate-requiring enzymes, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyl transferase (GARFT). The study recommendation is to continue to accrue patients and to follow the escalation schema as specified. Once the MTD has been achieved, this agent should be moved forward to the phase II setting